| Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in … P Harrington, KJ Doores, D Radia, A O’Reilly, HPJ Lam, J Seow, ... British journal of haematology 194 (6), 999-1006, 2021 | 67 | 2021 |
| Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study A Kizilors, E Crisà, N Lea, R Passera, S Mian, J Anwar, S Best, FE Nicolini, ... The Lancet Haematology 6 (5), e276-e284, 2019 | 58 | 2019 |
| Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative … P Harrington, H de Lavallade, KJ Doores, A O’Reilly, J Seow, C Graham, ... Leukemia 35 (12), 3573-3577, 2021 | 48 | 2021 |
| Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients P Harrington, KJ Doores, C Saha, J Saunders, F Child, R Dillon, ... Cancer cell 39 (11), 1448-1449, 2021 | 41 | 2021 |
| The role of early molecular response in the management of chronic phase CML P Harrington, A Kizilors, H de Lavallade Current Hematologic Malignancy Reports 12, 79-84, 2017 | 25 | 2017 |
| Ruxolitinib for the treatment of essential thrombocythemia A Gunawan, P Harrington, N Garcia-Curto, D McLornan, D Radia, ... HemaSphere 2 (4), e56, 2018 | 18 | 2018 |
| The development of focal segmental glomerulosclerosis secondary to anabolic steroid abuse P Harrington, G Ali, A Chan Case Reports 2011, bcr0720114531, 2011 | 17 | 2011 |
| Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys) J Okikiolu, C Woodley, L Cadman-Davies, J O'Sullivan, D Radia, ... Leukemia Research Reports 19, 100360, 2023 | 14 | 2023 |
| Evidence of robust memory T‐cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus‐2 (SARS … P Harrington, CN Harrison, R Dillon, DH Radia, K Rezvani, K Raj, ... British Journal of Haematology 193 (4), 692-696, 2021 | 13 | 2021 |
| Refractory severe immune thrombocytopenia in a twin pregnancy P Harrington, C Nelson-Piercy, C Williamson, N Cooper, R Kesse-Adu, ... Obstetric Medicine 11 (1), 35-38, 2018 | 11 | 2018 |
| Clinicopathological characterisation of myeloproliferative neoplasm‐unclassifiable (MPN‐U): a retrospective analysis from a large UK tertiary referral centre P Deschamps, M Moonim, D Radia, N Curto‐Garcia, C Woodley, ... British Journal of Haematology 193 (4), 792-797, 2021 | 10 | 2021 |
| Polycythemia Vera: Barriers to and Strategies for Optimal Management A Duminuco, P Harrington, C Harrison, N Curto-Garcia Blood and Lymphatic Cancer: Targets and Therapy, 77-90, 2023 | 8 | 2023 |
| Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib P Harrington, KJ Doores, J Saunders, M de Lord, C Saha, T Lechmere, ... Blood Cancer Journal 12 (4), 73, 2022 | 8 | 2022 |
| What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia? P Harrington, D Radia, H de Lavallade Expert Review of Hematology 13 (3), 213-222, 2020 | 8 | 2020 |
| Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype P Harrington, R Dillon, D Radia, D McLornan, C Woodley, S Asirvatham, ... British Journal of Haematology 198 (6), 1011-1015, 2022 | 7 | 2022 |
| Inhibition of immune cell subsets is differentially affected by dasatinib dosage in patients with chronic phase CML P Harrington, R Dillon, DH Radia, DP McLornan, P Rousselot, K Rezvani, ... Blood 136, 51-53, 2020 | 6 | 2020 |
| Beyond JAK-2: potential targets for myeloproliferative neoplasm therapy PM Harrington, CN Harrison Expert Review of Hematology 11 (4), 315-324, 2018 | 4 | 2018 |
| Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms A Duminuco, J Au Yeung, R Vaghela, S Virdee, C Woodley, S Asirvatham, ... Hemasphere 8 (8), e143, 2024 | 3 | 2024 |
| Novel developments in chronic myeloid leukaemia P Harrington, H de Lavallade Current Opinion in Hematology 28 (2), 122-127, 2021 | 3 | 2021 |
| Immunological effects of ponatinib therapy in patients with chronic myeloid leukaemia P Harrington, D Radia, M Lim, R Dillon, S Kordasti, K Rezvani, C Harrison, ... British Journal of Haematology 189, 72-73, 2020 | 3 | 2020 |
